Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Mar 31;13(3):458-462.
doi: 10.21037/tau-23-620. Epub 2024 Mar 12.

Biomarker challenges in the pursuit of personalized neoadjuvant chemotherapy for muscle-invasive bladder cancer: conclusions from SWOG S1314

Sandra Kim  1 , Marie-Pier St-Laurent  1 , Peter Black  1
Affiliations
Editorial

Biomarker challenges in the pursuit of personalized neoadjuvant chemotherapy for muscle-invasive bladder cancer: conclusions from SWOG S1314

Sandra Kim et al. Transl Androl Urol. .
No abstract available

Keywords: Bladder neoplasms; CO-eXpression ExtrapolatioN (COXEN); biomarkers; neoadjuvant therapy; tumor.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tau.amegroups.com/article/view/10.21037/tau-23-620/coif). M.P.S.L. has received honoraria from Bayer and EMD Serono and is an unpaid research collaborator for Veracyte, all outside of the present manuscript. P.B. has received consulting fees for AbbVie, AstraZeneca, Astellas, Bayer, BMS, Combat, EMD-Serono, Ferring, Janssen, Merck, Nonagen, Nanobot, NanOlogy, Pfizer, Photocure, Prokarium, Sumitomo, TerSera, Tolmar, and Verity; has received honoraria from Janssen, TerSera, Bayer, and Pfizer; and shares patent with Veracyte. The other author has no conflicts of interest to declare.

Comment on

References

    1. Flaig TW, Tangen CM, Daneshmand S, et al. A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695). Clin Cancer Res 2021;27:2435-41. 10.1158/1078-0432.CCR-20-2409 - DOI - PMC - PubMed
    1. Flaig TW, Tangen CM, Daneshmand S, et al. Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695). Eur Urol 2023;84:341-7. 10.1016/j.eururo.2023.06.014 - DOI - PMC - PubMed
    1. Zhu Y, Brettin T, Evrard YA, et al. Enhanced Co-Expression Extrapolation (COXEN) Gene Selection Method for Building Anti-Cancer Drug Response Prediction Models. Genes (Basel) 2020;11:1070. 10.3390/genes11091070 - DOI - PMC - PubMed
    1. Smith SC, Baras AS, Lee JK, et al. The COXEN principle: translating signatures of in vitro chemosensitivity into tools for clinical outcome prediction and drug discovery in cancer. Cancer Res 2010;70:1753-8. 10.1158/0008-5472.CAN-09-3562 - DOI - PMC - PubMed
    1. Lee JK, Havaleshko DM, Cho H, et al. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci U S A 2007;104:13086-91. 10.1073/pnas.0610292104 - DOI - PMC - PubMed